Mark T Bertolini

CEO Mark T Bertolini sells 1,238,996 shares for $35,767,321.70 at OSCR via pre-arranged 10b5-1 plan

Mark T Bertolini, CEO of Oscar Health, executed 4 separate sales totaling 1,238,996 shares for $35,767,321.70 at a blended average price of $28.87 on June 29–30, 2026. The transaction reduces his holdings from 8,990,566 shares to 7,751,570 shares, a reduction of 13.8%. This sale is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than discretionary. The stock has appreciated 38.9% over the prior 30 days and 167.6% over 90 days, and currently trades at $31.90, near its 52-week high of $32.06. While the company posted strong recent quarterly revenue of $4,647,194,000.00 and net income of $678,996,000.00, full-year fundamentals show the company was unprofitable over its most recent full fiscal year, warranting attention to underlying profitability trends despite near-term gains.

CEO Mark Bertolini sells 1.21M OSCR shares for $34.9M via scheduled 10b5-1 plan

Mark T Bertolini, Chief Executive Officer of Oscar Health, filed 4 separate sales on 2026-06-25 and 2026-06-26 totaling 1,206,310 shares for $34,912,078.28, reducing his holdings from 10.20M to 8.99M shares (-11.8%). This sale is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled and non-discretionary. The blended average sale price of $28.94 compares to a current price of $29.45, against a 52-week high of $30.66 and a 30-day price change of +32.5%. Fundamentals show the company posted revenue of $4.6B and net income of $679.0M in the latest quarter, with annual revenue growth of +27.5%, though the company was unprofitable over its most recent full fiscal year. The scheduled nature of this transaction under a 10b5-1 plan precludes timing-based interpretation; investors should note the dollar magnitude ($34.9M) and percentage reduction in holdings (-11.8%) alongside the recent strong price momentum and mixed profitability profile.

CEO Mark T Bertolini buys 1,000,000 shares of OSCR at $11.92, increasing stake 10.9%; stock down 42.3% from 52-week high.

Bertolini's purchase of 1,000,000 shares at $11.92 represents a material addition to his stake (10.9% increase from 9,196,876 to 10,196,876 shares), executed while OSCR trades 42.3% below its 52-week high of $22.47 and has declined 21.3% over the past 90 days. The company's fundamentals remain mixed: revenue reached $3.0B with strong 27.5% year-over-year growth, but Oscar Health remains unprofitable with net income of $-137.4M in the latest full fiscal year. The timing and scale of a CEO's open-market share purchase warrant investor attention given the stock's recent underperformance, though the purchase itself offers no direct insight into management's forward expectations without additional context about capital allocation strategy or stated rationale.